source
- Biogen sees continued revenue growth and pipeline readouts, M&A not essential, CEO saysBiogen reported third‑quarter earnings, marking a third straight quarter of revenue growth driven by its marketed products. The increase stemmed from higher sales of the Alzheimer’s therapy Leqemb…
- Biogen posts third consecutive quarter of revenue growth, driven by Leqembi, Spinraza and Apellis productsBiogen reported $2.8 billion in revenue for the third quarter, marking its third straight period of top‑line growth. The company credited its growth portfolio, led by the Alzheimer’s therapy Leqem…